TrialBlood2021

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.

Anthony R Mato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.